Suven Pharmaceuticals to acquire controlling stake in NJ Bio

07 Dec 2024 Evaluate

Suven Pharmaceuticals is all set to acquire a controlling stake in NJ Bio Inc. (NJ Bio) with an investment of $64.4 million. Based in Princeton, NJ Bio is a premier ADC/XDC-focused CRDMO offering cutting-edge solutions across the ADC value chain.

This acquisition positions the company as a key player in one of the fastest growing segments of the Pharma CDMO landscape and it also extends the company’s current ADC offering with expertise across payload chemistry, payload-linker synthesis, bioconjugation, and AD specific analytical platform. The transaction is expected to close before the end of December 2024.

Suven Pharmaceuticals is India’s leading technology-focused CDMO, offering integrated solutions in custom synthesis, process R&D, and manufacturing for global innovators.


Suven Pharma Share Price

1157.55 -51.20 (-4.24%)
27-Feb-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1647.60
Dr. Reddys Lab 1125.90
Cipla 1441.15
Lupin 1891.45
Zydus Lifesciences 886.50
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
Loading...
Hold on